Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

VitaNova Life Sciences (YJGJ) Shares Outstanding (Weighted Average) (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Shares Outstanding (Weighted Average) for 8 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) changed 0.0% year-over-year to $25.0 million, compared with a TTM value of $25.0 million through Oct 2025, changed 0.0%, and an annual FY2025 reading of $25.0 million, up 135.0% over the prior year.
  • Shares Outstanding (Weighted Average) was $25.0 million for Q4 2025 at VitaNova Life Sciences, roughly flat from $25.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $25.0 million in Q3 2024 and bottomed at $5.9 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $11.9 million, with a median of $5.9 million recorded in 2021.
  • The sharpest move saw Shares Outstanding (Weighted Average) changed 0.0% in 2021, then soared 326.01% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $5.9 million in 2021, then changed by 0.0% to $5.9 million in 2022, then changed by 0.0% to $5.9 million in 2023, then skyrocketed by 326.01% to $25.0 million in 2024, then changed by 0.0% to $25.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for YJGJ at $25.0 million in Q4 2025, $25.0 million in Q3 2025, and $25.0 million in Q2 2025.